Poly(I:C) enhances vaccination-supported adoptive T-cell therapy associated with remodeling of the tumor immune microenvironment in sarcoma
Frontiers in Immunology · 16.11.2026 · 17
DOI: 10.3389/fimmu.2026.1925101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 16.11.2026. Verfasst von Situo Deng und 9 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takara Bio.
Abstract (Originalsprache)
Background
The efficacy of adoptive cell therapy (ACT) in solid tumors is often constrained by an unfavorable tumor microenvironment. Poly(I:C)-mediated innate immune activation can enhance antitumor immunity; however, its impact on the sarcoma immune microenvironment during ACT remains unclear.
Methods
We evaluated the therapeutic and immune-modulatory effects of poly(I:C) in vaccine-augmented ACT in murine sarcoma models. Flow cytometry was used to assess tumor-infiltrating CD8 + T cells and myeloid populations, and intracellular cytokine staining was performed after ex vivo restimulation. Public bulk RNA-seq datasets from poly(I:C)-treated murine sarcoma and single-cell RNA-seq data from human sarcoma treated with radiotherapy with or without BO-112 were analyzed to identify treatment-associated immune programs. The clinical relevance of TLR3-associated immune activation was evaluated using the TCGA-SARC cohort.
Results
Poly(I:C) enhanced the efficacy of vaccination-supported ACT, inducing marked tumor control in antigen-positive CMS5a sarcoma and CT26/9m tumor models, with complete regression observed in a subset of tumor-bearing mice. This was associated with increased intratumoral accumulation of adoptively transferred CD8 + T cells, enhanced functional responsiveness of tumor-infiltrating CD8 + T cells, and substantial remodeling of Ly6C/MHCII-defined myeloid cell populations. Bulk transcriptomic analyses of poly(I:C)-treated murine sarcoma identified coordinated interferon-response, antigen-presentation, myeloid/APC, and cytotoxic immune programs, whereas single-cell analysis of human sarcoma identified treatment-associated remodeling of myeloid states and antigen-presentation programs. Higher TLR3 expression and TLR3-associated immune activation signatures were associated with favorable survival in TCGA-SARC.
Conclusions
Addition of poly(I:C) reshapes the sarcoma immune microenvironment, particularly in myeloid compartments, and enhances the efficacy of ACT against antigen-positive tumors. These findings support further investigation of poly(I:C)-based innate immune activation as a strategy to improve vaccination-supported ACT in solid tumors and suggest that myeloid remodeling associated with enhanced antigen-presentation capacity is linked to improved intratumoral CD8 + T-cell responses.
Förderung
- Takara Bio
Zitieren
APA
Deng, S., Muraoka, D., Yasui, K., Yoneda, M., Miao, P., Jiang, C., Sun, H., Meng, X., Akiyoshi, K., & Ikeda, H. (2026). Poly(I:C) enhances vaccination-supported adoptive T-cell therapy associated with remodeling of the tumor immune microenvironment in sarcoma. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1925101
Vancouver
Deng S, Muraoka D, Yasui K, Yoneda M, Miao P, Jiang C, et al. Poly(I:C) enhances vaccination-supported adoptive T-cell therapy associated with remodeling of the tumor immune microenvironment in sarcoma. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1925101
BibTeX
@article{Deng2026,
author = {Deng, Situo and Muraoka, Daisuke and Yasui, Kiyoshi and Yoneda, Mitsuhiro and Miao, Pengyu and Jiang, Chenxu and Sun, Huimin and Meng, Xiangyue and Akiyoshi, Kazunari and Ikeda, Hiroaki},
title = {Poly(I:C) enhances vaccination-supported adoptive T-cell therapy associated with remodeling of the tumor immune microenvironment in sarcoma},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1925101}
}
EUVIMED